Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
Haslam A, Gill J, Prasad V
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1001/jamanetworkopen.2020.0423
- Published
- Mar 2, 2020
- Venue
- JAMA network open
- DOI
- 10.1001/jamanetworkopen.2020.0423
- PubMed
- 32150268
- PMC
- PMC7063495
- License
- CC-BY
- Provenance
- europepmc